Source-grounded facts extracted from Sarepta Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sarepta Therapeutics, Inc. reported first quarter 2026 results: revenue $330.5 million, net income $331.0 million, EPS $2.88. Guidance reaffirmed.
“Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments – Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively”
Debt Financings
Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.
“the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.”
Debt Financings
Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.
“party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par”
Restructurings & Charges
Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).
“on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million”
Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..
“Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.”
Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..
“Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.”
Deirdre Connelly was appointed as Director at Sarepta Therapeutics, Inc..
“On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.